Dianthus Therapeutics, Inc. stock is down -16.67% since 30 days ago. The next earnings date is Feb 3, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 5 December’s closed higher than November. 100% of analysts rate it a buy.
Magenta Therapeutics develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibody that targets hematopoietic stem cells and genetically mutated stem cells that cause acute myeloid leukemia and myelodysplastic syndromes. The company also has a cell therapy program, E478, which is a small molecule aryl hydrocarbon receptor antagonist for stem cell-based gene therapy.